University of Colorado School of Medicine Internal Medicine/Pediatrics

Topics

• Cystic Fibrosis Research Advances 136
• Asthma and respiratory diseases 51
• Hemophilia Treatment and Research 45
• Neonatal Respiratory Health Research 36
• Acute Kidney Injury Research 19
• Hepatitis C virus research 18
• Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 18
• HIV/AIDS Research and Interventions 16
• Hospital Admissions and Outcomes 14
• Innovations in Medical Education 14
• Acute Ischemic Stroke Management 13
• Sinusitis and nasal conditions 12

Most cited

1. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.

   The New England journal of medicine · 2022 · 396 citations · Hillary Dunlevy

2. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.

   The Lancet. Respiratory medicine · 2025 · 92 citations · Jennifer Taylor-Cousar

3. Cystic fibrosis.

   Nature reviews. Disease primers · 2024 · 168 citations · Jennifer Taylor-Cousar

4. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry.

   Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024 · 86 citations · Flavia Hoyte

5. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.

   American journal of respiratory and critical care medicine · 2021 · 251 citations · Jennifer Taylor-Cousar

6. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.